Advancing outcomes of metastatic HER2-positive breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advancing outcomes of metastatic HER2-positive breast cancer

Published:2023-05 Issue:10390 Volume:401 Page:1746-1747
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Chumsri Saranya

Publisher

Elsevier BV

Subject

General Medicine

Reference11 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Strategies and challenges for the next generation of antibody-drug conjugates;Beck;Nat Rev Drug Discov,2017

3. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers;Yver;Ann Oncol,2020

4. Targeting HER2-positive breast cancer: advances and future directions;Swain;Nat Rev Drug Discov,2023

5. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;Modi;N Engl J Med,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC;Journal of Pharmaceutical Analysis;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP